Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing The Potential Breadth Of The Study
Portfolio Pulse from Benzinga Newsdesk
Genprex has decided to cease enrollment in the Acclaim-2 clinical trial due to difficulties in recruiting patients, citing competition from numerous other trials. Additionally, the company is limiting the Acclaim-1 trial to a single cohort due to resource prioritization, reducing the potential breadth of the study.
August 14, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Genprex has halted enrollment in the Acclaim-2 clinical trial due to recruitment challenges and is limiting the Acclaim-1 trial to a single cohort due to resource prioritization.
The decision to halt enrollment in the Acclaim-2 trial and limit the Acclaim-1 trial to a single cohort indicates potential setbacks in Genprex's clinical development pipeline. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100